162 related articles for article (PubMed ID: 23659474)
1. Improving the in vivo persistence, distribution and function of cytotoxic T lymphocytes by inhibiting the tumor immunosuppressive microenvironment.
Xu W; Cai J; Li S; Zhang H; Han J; Wen M; Wen J; Gao F
Scand J Immunol; 2013 Jul; 78(1):50-60. PubMed ID: 23659474
[TBL] [Abstract][Full Text] [Related]
2. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
[TBL] [Abstract][Full Text] [Related]
3. Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma.
Wen M; Xu W; Ren L; Gao F; Cui N; Wen J; Li X; Lin L; Ma Z; Chen B; Cai J
Chin Med J (Engl); 2014; 127(7):1328-33. PubMed ID: 24709189
[TBL] [Abstract][Full Text] [Related]
4. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation.
Krause M; Schmitz M; Noessner E; Skrablin PS; Wehner R; Rieber EP; Baumann M
Int J Radiat Biol; 2007; 83(11-12):827-36. PubMed ID: 17852560
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice.
Lynch DH; Miller RE
Eur J Immunol; 1991 Jun; 21(6):1403-10. PubMed ID: 1904359
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction.
Asselin-Paturel C; Megherat S; Vergnon I; Echchakir H; Dorothée G; Blesson S; Gay F; Mami-Chouaib F; Chouaib S
Cancer; 2001 Jan; 91(1):113-22. PubMed ID: 11148567
[TBL] [Abstract][Full Text] [Related]
8. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
9. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
11. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.
Cui NP; Xie SJ; Han JS; Ma ZF; Chen BP; Cai JH
Chin Med J (Engl); 2012 Mar; 125(5):794-800. PubMed ID: 22490577
[TBL] [Abstract][Full Text] [Related]
12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
13. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice.
Sabzevari H; Reisfeld RA
Cancer Res; 1993 Oct; 53(20):4933-7. PubMed ID: 8402683
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
Terabe M; Matsui S; Park JM; Mamura M; Noben-Trauth N; Donaldson DD; Chen W; Wahl SM; Ledbetter S; Pratt B; Letterio JJ; Paul WE; Berzofsky JA
J Exp Med; 2003 Dec; 198(11):1741-52. PubMed ID: 14657224
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation of curcumin on adoptive therapy with T cell functional imaging in mice.
Chang YF; Chuang HY; Hsu CH; Liu RS; Gambhir SS; Hwang JJ
Cancer Prev Res (Phila); 2012 Mar; 5(3):444-52. PubMed ID: 22135043
[TBL] [Abstract][Full Text] [Related]
16. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
[TBL] [Abstract][Full Text] [Related]
17. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
18. A tumor-specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T-lymphocyte activation in mice.
Shen Y; Fujimoto S
Cancer Res; 1996 Nov; 56(21):5005-11. PubMed ID: 8895757
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells.
Loeffler CM; Smyth MJ; Longo DL; Kopp WC; Harvey LK; Tribble HR; Tase JE; Urba WJ; Leonard AS; Young HA
J Immunol; 1992 Aug; 149(3):949-56. PubMed ID: 1353099
[TBL] [Abstract][Full Text] [Related]
20. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
